ProShare Advisors LLC Has $1.48 Million Stock Holdings in United Therapeutics Co. (NASDAQ:UTHR)

ProShare Advisors LLC trimmed its holdings in United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 54.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 4,203 shares of the biotechnology company's stock after selling 4,935 shares during the period. ProShare Advisors LLC's holdings in United Therapeutics were worth $1,483,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wealthfront Advisers LLC boosted its position in shares of United Therapeutics by 2,090,573.5% during the fourth quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company's stock worth $6,462,018,000 after buying an additional 18,313,424 shares during the period. Vanguard Group Inc. boosted its position in shares of United Therapeutics by 0.7% during the fourth quarter. Vanguard Group Inc. now owns 4,441,823 shares of the biotechnology company's stock worth $1,567,253,000 after buying an additional 32,213 shares during the period. FMR LLC boosted its position in shares of United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company's stock worth $519,170,000 after buying an additional 393,777 shares during the period. Geode Capital Management LLC boosted its position in shares of United Therapeutics by 4.0% during the fourth quarter. Geode Capital Management LLC now owns 1,138,292 shares of the biotechnology company's stock worth $401,184,000 after buying an additional 44,277 shares during the period. Finally, AQR Capital Management LLC boosted its position in shares of United Therapeutics by 0.8% during the fourth quarter. AQR Capital Management LLC now owns 975,444 shares of the biotechnology company's stock worth $344,176,000 after buying an additional 7,710 shares during the period. 94.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 11,000 shares of the stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $306.18, for a total transaction of $3,367,980.00. Following the transaction, the executive vice president now owns 36,781 shares in the company, valued at approximately $11,261,606.58. This trade represents a 23.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Tommy G. Thompson sold 2,500 shares of the stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the transaction, the director now owns 8,480 shares in the company, valued at approximately $2,703,424. This trade represents a 22.77% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 45,500 shares of company stock worth $13,447,180 over the last 90 days. Company insiders own 10.30% of the company's stock.

United Therapeutics Trading Up 0.8%

NASDAQ:UTHR traded up $2.41 on Tuesday, hitting $310.06. The company's stock had a trading volume of 63,344 shares, compared to its average volume of 441,242. The stock has a fifty day moving average of $299.41 and a two-hundred day moving average of $336.74. The firm has a market capitalization of $13.99 billion, a P/E ratio of 13.63, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. United Therapeutics Co. has a one year low of $264.33 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last released its quarterly earnings data on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.29 by $0.34. The firm had revenue of $794.40 million for the quarter, compared to analyst estimates of $726.82 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The business's revenue for the quarter was up 17.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $6.17 earnings per share. As a group, sell-side analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on UTHR shares. HC Wainwright reaffirmed a "buy" rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. Wells Fargo & Company reiterated an "equal weight" rating and set a $314.00 target price (down previously from $395.00) on shares of United Therapeutics in a report on Friday, April 25th. Bank of America upgraded United Therapeutics from an "underperform" rating to a "neutral" rating and set a $314.00 target price on the stock in a report on Monday, April 21st. Wall Street Zen lowered United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Finally, Morgan Stanley upped their target price on United Therapeutics from $346.00 to $348.00 and gave the stock an "equal weight" rating in a report on Thursday, May 1st. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $392.00.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.